Background
==========

Programmed death (PD)-1 is a newly described member of the immunoglobulin super-family that is expressed on activated T lymphocytes and B lymphocytes. Engagement of PD-1 with its specific ligands, PD-L1 (B7-H1) and PD-L2 (B7-DC), inhibits lymphocyte proliferation and cytokine expression, and may play a role in peripheral tolerance and negative regulation of T-cell and B-cell responses *in vivo*. We sought to investigate the expression profiles of PD-1 and PD-1 ligands in peripheral blood cells of patients with systemic lupus erythematosus (SLE).

Materials and methods
=====================

Blood was drawn from patients with SLE (*n*= 16), rheumatoid arthritis (*n*= 16), other inflammatory disease (*n*= 4), and healthy controls (*n*= 9). Peripheral blood mononuclear cells were separated on a ficoll-density gradient, and flow cytometry analysis was performed using monoclonal antibodies against CD3, CD19, CD14, CD25, CD69, PD-1, PD-L1, and PD-L2.

Results
=======

See Table [1](#T1){ref-type="table"}.

                Disease group                                         
  ------------- --------------- ----- ------ ----- ----- ----- ------ -----
  PD-1^+^(%)                                                          
   in CD3^+^    0.6             0.2   0.4    0.1   1.6   0.6   0.5    0.1
   in CD19^+^   1.7             0.9   1.4    0.3   0.9   0.4   1.1    0.4
   in CD25^+^   3.0             1.0   2.4    0.7   3.3   1.6   8.5    3.4
  PD-L1^+^(%)                                                         
   in CD3^+^    2.8             1.2   4.1    0.9   2.3   0.5   2.0    0.6
   in CD19^+^   3.9             1.3   5.1    0.9   3.7   1.0   11.3   8.0
   in CD14^+^   5.1             2.0   14.0   5.4   2.9   0.9   5.7    3.2
  PD-L2^+^(%)                                                         
   in CD3^+^    0.6             0.2   0.5    0.1   0.5   0.2   0.4    0.0
   in CD14^+^   2.0             0.5   1.4    0.3   1.1   0.5   1.2    0.1

SEM, standard error of the mean. No statistically significant differences were observed.

Conclusions
===========

In this preliminary report, SLE patients showed a trend for lower expression of PD-1 and higher expression of PD-L1 in unstimulated peripheral blood mononuclear cells compared with other disease controls. These results corroborate findings linking SLE with polymorphism of the PD-1 gene resulting in putative altered expression of the PD-L2 \[[@B1]\]. Lower expression of PD-1 in SLE lymphocytes could be related to ineffective suppression of autoreactive lymphocytes and thus to disease evolution. Currently, we investigate expression of PD-1 and its ligands on subpopulations of lymphocytes (CD45RO^+^, CD27^+^), as well as the kinetics of expression upon stimulation.
